Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
Juanjuan Zhao, Quan Ren, Xinyuan Liu, Xiangqian Guo, Yongping Song
Abstract
Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment of MM from the ASCO 2023 Annual Meeting.
Topics & Concepts
MedicineBispecific antibodyClinical trialMultiple myelomaInternal medicineOncologyHematologyMedical physicsAntibodyImmunologyMonoclonal antibodyMonoclonal and Polyclonal Antibodies ResearchMultiple Myeloma Research and TreatmentsGlycosylation and Glycoproteins Research